1. KD. Tripathi. Cardiac Glycosides and Drugs for Heart Failure. Essentials of medical pharmacology. Seventh edition. 2013. Page – 512-519.
2. Kevin J. Sampson and Robert S. Kass. Anti-Arrhythmic Drugs. Goodman & Gilman’s: The Pharmacological basics of Therapeutics. 12th Edition. New York McGraw Hill Medical 2011. Page – 837-839.
3. Gerald G. Briggs and Roger K. Freeman. D. A reference guide to fetal and neonatal risk: Drugs in Pregnancy and Lactation. Tenth Edition. 2015. Page – 1172-1174.
4. National Heart, Lung, and Blood Institute (NHLBI). Digitalis Investigation Group (DIG). NIH U.S. National Library of Medicine ClinicalTrials.gov. [Revised on July 2016] [Accessed 30th January 2021] https://clinicaltrials.gov/ct2/show/NCT00000476
5. R A Kelly and T W Smith. Digoxin in heart failure: implications of recent trials. NIH National Library of Medicine, National center for biotechnology information. Pubmed.gov. October 1993. [Accessed 30th January 2021] https://pubmed.ncbi.nlm.nih.gov/8376681/
6. Sebastiano Virgadamo, Richard Charnigo, Yousef Darrat, Gustavo Morales and Claude S Elayi. Digoxin: A systematic review in atrial fibrillation, congestive heart failure and post myocardial infarction. NCBI; PMC US National Library of Medicine, National Institute of Health. November 2015. [Accessed 30th January 2021] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4660476/
7. Aspen Bad Oldesloe GmbH. Electronic Medicines Compendium (EMC); [Revised on December 2019] [Accessed 30th January 2021] https://www.medicines.org.uk/emc/files/pil.5463.pdf